Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human BTLA (31-134) Protein, Fc Tag, 100µg  

Recombinant Human BTLA (31-134) Protein, Fc Tag, 100µg

Recombinant Human BTLA (31-134) Protein, Fc Tag, AA Lys 31 - Thr 134, was produced in human 293 cells (HEK293).

Synonym: recombinant, human, protein, BTLA,CD272

More details

BTA-H5255-100

Availability: within 7 days

468,00 €

Background
B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Source
Recombinant Human BTLA, Fc Tag (BTA-H5255) is expressed from human 293 cells (HEK293). It contains AA Lys 31 - Thr 134 (Accession # NP_001078826.1).
Predicted N-terminus: Lys 31

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 38.7 kDa. The protein migrates as 45-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>92% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "[Expression of BTLA/HVEM axis in hematological and prospects for immune target therapy]"
Li, Zhang, Feng et al
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2025) 41 (1), 64-70
(2) "Integrated Analysis of Single-Cell and Bulk RNA Data Reveals Complexity and Significance of the Melanoma Interactome"
Diaz, Tran, Samia et al
Cancers (Basel) (2025) 17 (1)
(3) "Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients"
Aubergeon, Felten, Gottenberg et al
Cells (2024) 13 (24)
Showing 1-3 of 735 papers.